Outpatient And Life Science Trends Will Create Future Opportunities

Published
21 Aug 24
Updated
20 Aug 25
AnalystConsensusTarget's Fair Value
US$22.41
21.2% undervalued intrinsic discount
20 Aug
US$17.65
Loading
1Y
-20.8%
7D
2.5%

Author's Valuation

US$22.4

21.2% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on19 Aug 25
Fair value Decreased 0.28%

Healthpeak Properties’ fair value saw a marginal decrease as a slight drop in its future P/E multiple reflected modestly softer forward expectations. What's in the News Completed share repurchase program, buying 5,091,156 shares (0.73%) for $94.17 million.

Shared on04 Aug 25

Healthpeak Properties saw a slight decrease in its future P/E ratio alongside an effectively unchanged discount rate, resulting in a marginal reduction in the consensus analyst price target from $22.47 to $22.41. What's in the News Repurchased 3,944,683 shares for $71.87 million, completing a total buyback of 5,091,156 shares for $94.17 million under the current program.

Shared on07 May 25
Fair value Decreased 8.33%

Shared on30 Apr 25
Fair value Decreased 7.65%

AnalystConsensusTarget has decreased revenue growth from 3.9% to 3.5%.

Shared on23 Apr 25
Fair value Increased 2.12%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on16 Apr 25
Fair value Decreased 0.73%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Decreased 0.15%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 4.30%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on10 Mar 25
Fair value Increased 11%

AnalystConsensusTarget has decreased revenue growth from 6.0% to 3.7%.